Sector News

Will docs jump on new biosims? Survey shows they’ll need some nudging

August 17, 2015
Life sciences
Drugmakers are well aware of the biosimilars threatening to steal sales and market share from some of the world’s best-selling biologics.
 
Doctors, though? Not so much, a new report suggests.
 
Doctor platform and community QuantiaMD recently surveyed 300 primary care physicians and specialists to find out just how much healthcare providers knew about the drugs. 78% of those polled said they were familiar with the term “biosimilar,” but only 38% could name one under consideration for FDA approval that would be relevant to their patients, Medical Marketing & Media report.
 
To make matters worse, only 17% of the doctors Quantia deemed most likely to prescribe biologics–and, thus, the most likely to prescribe biosimilars in the future–said they were “very likely” to do so. 70% said they either weren’t sure or were “somewhat likely” to write a biosimilar script.
 
That’s a problem for the copycat pharmas looking to steal a piece of the pie from blockbusters like Amgen’s Neupogen, AbbVie’s Humira and Johnson & Johnson’s Remicade. Whether biosimilars pick up steam will largely depend on doctors–and on their likelihood to order them for patients.
 
Right now, only one biosimilar has FDA approval, and that’s Zarxio, a Novartis copy of Neupogen that won’t roll out until September, per court orders.
 
In the meantime, though, what can drugmakers do to get the word out to docs? “There’s a lot of opportunity for education,” Rachel Daricek, QuantiaMD’s senior director of client services, told MM&M. ” … They haven’t seen any efficacy and safety data or seen any communication from pharma or their organization–they don’t know what to think.”
 
By Carly Helfand
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).